Page 1, 2
1. Nejat EJ, Polotsky AJ, Pal L. Predictors of chronic disease at midlife and beyond – the health risks of obesity. Maturitas. 2010;65:106–111.
2. Forouhi NG, Wareham NJ. Epidemiology of diabetes. Medicine (Abingdon). 2014;42:698–702.
3. Wang Y, Beydoun MA. The obesity epidemic in the United States – gender, age, socioeconomic, racial/ethnic, and geographic characteristics: a systematic review and meta-regression analysis. Epidemiol Rev. 2007;29:6–28.
4. Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract. 2014;2014:943162.
5. Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56:1113–1132.
6. Wong ND. Intensified screening and treatment of the metabolic syndrome for cardiovascular risk reduction. Prev Cardiol. 2005;8:47–52.
7. Atallah R, Filion KB, Wakil SM, et al. Long-term effects of 4 popular diets on weight loss and cardiovascular risk factors: a systematic review of randomized controlled trials. Circ Cardiovasc Qual Outcomes. 2014;7:815–827.
8. Van Gaal LF, Wauters MA, De Leeuw IH. The beneficial effects of modest weight loss on cardiovascular risk factors. Int J Obes Relat Metab Disord. 1997;21 Suppl 1:S5–S9.
9. Hill JO, Wyatt HR. Role of physical activity in preventing and treating obesity. J Appl Physiol. 2005;99:765–770.
10. Goedecke JH, Micklesfield LK. The effect of exercise on obesity, body fat distribution and risk for type 2 diabetes. Med Sport Sci. 2014;60:82–93.
11. Duncan GE, Perri MG, Theriaque DW, Hutson AD, Eckel RH, Stacpoole PW. Exercise training, without weight loss, increases insulin sensitivity and postheparin plasma lipase activity in previously sedentary adults. Diabetes Care. 2003;26:557–562.
12. Terranova CO, Brakenridge CL, Lawler SP, Eakin EG, Reeves MM. Effectiveness of lifestyle-based weight loss interventions for adults with type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. Epub 2014 Dec 19.
13. MacLean PS, Wing RR, Davidson T, et al. NIH working group report: Innovative research to improve maintenance of weight loss. Obesity (Silver Spring). 2015;23:7–15.
14. Franz MJ, Bantle JP, Beebe CA, et al. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care. 2003;26 Suppl 1:S51–S61.
15. Chutkan R, Fahey G, Wright WL, McRorie J. Viscous versus nonviscous soluble fiber supplements: mechanisms and evidence for fiber-specific health benefits. J Am Acad Nurse Pract. 2012;24:476–487.
16. Del Valle EM. Cyclodextrins and their uses: a review. Process Biochem. 2004;39:1033–1046.
17. Van der Veen BA, Uitdehaag JC, Penninga D, et al. Rational design of cyclodextrin glycosyltransferase from Bacillus circulans strain 251 to increase alpha-cyclodextrin production. J Mol Biol. 2000;296:1027–1038.
18. Buschmann HJ, Schollmeyer E. Applications of cyclodextrins in cosmetic products: a review. J Cosmet Sci. 2002;53:185–191.
19. Irie T, Uekama K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J Pharm Sci. 1997;86:147–162.
20. Artiss JD, Brogan K, Brucal M, Moghaddam M, Jen KL. The effects of a new soluble dietary fiber on weight gain and selected blood parameters in rats. Metabolism. 2006;55:195–202.
21. Antenucci RN, Palmer JK. Enzymatic degradation of α- and β-cyclodextrins by bacteroides of the human colon. J Agric Fd Chem. 1984;32:1316–1321.
22. Kaewprasert S, Okada M, Aoyama Y. Nutritional effects of cyclodextrins on liver and serum lipids and cecal organic acids in rats. J Nutr Sci Vitaminol (Tokyo). 2001;47:335–339.
23. Gallaher D, Gallaher C, Plank D. Alpha-cyclodextrin selectively increases fecal excretion of saturated fats. FASEB J. 2007;21:A730.
24. Grunberger G, Jen KL, Artiss JD. The benefits of early intervention in obese diabetic patients with FBCx: a new dietary fibre. Diabetes Metab Res Rev. 2007;23:56–62.
25. Comerford KB, Artiss JD, Jen KL, Karakas SE. The beneficial effects of α-cyclodextrin on blood lipids and weight loss in healthy humans. Obesity (Silver Spring). 2011;19:1200–1204.
26. Waki H, Tontonoz P. Endocrine functions of adipose tissue. Annu Rev Pathol. 2007;2:31–56.
27. Jacobson TA. Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk. Mayo Clin Proc. 2011;86:762–780.
28. Jarosz PA, Fletcher E, Elserafy E, Artiss JD, Jen KL. The effect of α-cyclodextrin on postprandial lipid and glycemic responses to a fat-containing meal. Metabolism. 2013;62:1443–1447.
29. Kannel WB, Vasan RS. Triglycerides as vascular risk factors: new epidemiologic insights. Curr Opin Cardiol. 2009;24:345–350.
30. Wagner EM, Jen KL, Artiss JD, Remaley AT. Dietary alpha-cyclodextrin lowers low-density lipoprotein cholesterol and alters plasma fatty acid profile in low-density lipoprotein receptor knockout mice on a high-fat diet. Metabolism. 2008;57:1046–1051.
31. Furune T, Ikuta N, Ishida Y, et al. A study on the inhibitory mechanism for cholesterol absorption by a-cyclodextrin administration. Beilstein J Org Chem. 2014;10:2827–2835.
32. Pranckute R, Kaunietis A, Kuisiene N, Citavicius D. Development of synbiotics with inulin, palatinose, alpha-cyclodextrin and probiotic bacteria. Pol J Microbiol. 2014;63:33–41.
33. Buckley JD, Thorp AA, Murphy KJ, Howe PR. Dose-dependent inhibition of the post-prandial glycaemic response to a standard carbohydrate meal following incorporation of alpha-cyclodextrin. Ann Nutr Metab. 2006;50:108–114.
34. Koukiekolo R, Desseaux V, Moreau Y, Marchis-Mouren G, Santimone M. Mechanism of porcine pancreatic alpha-amylase. Inhibition of amylose and maltopentaose hydrolysis by alpha-, beta- and gamma-cyclodextrins. Eur J Biochem. 2001;268:841–848.
Stephen F. Olmstead, MD, is chief science officer at ProThera Inc., where he oversees technical and scientific services. He is an internationally recognized biofilm expert, and his current research focus is on the use of enzymes and chelating agents to disrupt pathogenic gastrointestinal and systemic biofilms. Dr. Olmstead authors nationally published scientific articles and technical summaries and hosts webinars designed for health-care providers. Dr. Olmstead graduated from the University of New Mexico with distinction in biology and chemistry. He attended the University of New Mexico School of Medicine and trained at Harvard Medical School, Massachusetts General Hospital. He is board certified in both internal medicine and cardiovascular diseases.
Page 1, 2